What is Belviq and How Does it Work?
Belviq (lorcaserin) is a well-known weight reduction drug. The medication is sold and delivered by Eisai Inc., a Tokyo-based drug maker. Belviq was at first affirmed by the FDA in 2012 for U.S. markets. Belviq changes the brain’s chemical signals liable for craving and expands sentiments of totality to assist patients with losing weight. The medication is utilized as a consolidated treatment with diet and exercise to help grown-ups who are overweight, stout, or enduring weight-related clinical issues. Belviq is occasionally recommended to treat heftiness connected to diabetes, hypertension, and elevated cholesterol, however, it doesn’t treat hidden health conditions.
Is Belviq Dangerous?
The Food and Drug Administration (FDA) mentioned that Eisai Inc. pulls back Belviq from U.S. markets referring to worries over the medication’s connections to cancer. Since Belviq was affirmed in 2012, specialists have been contemplating medicine’s safety. The FDA initially necessitated that the medication producer leads a double-blind, randomized, fake treatment controlled clinical preliminary that tested for dangers of heart-related medical issues.
The specialists investigated around 12,000 participants, some of who were given Belviq while some took a fake treatment. Scientists didn’t find resulting heart issues attached to Belviq, however, they found that patients taking the medication had a higher cancer growth rate than the individuals who took a fake treatment.
If you get prescribed Belviq drug for whatever reason by a doctor or you have been using Belviq and see symptoms mentioned below, please contact a belviq attorney.
Research Links Belviq to Cancer
FDA analysts found expanded paces of cancer in patients prescribed Belviq. About 7.7 percent of patients who took Belviq had a disease cancer contrasted with 7.1 percent who got a fake treatment. Through the span of the experimental, 662 Belviq patients were diagnosed with 520 primary malignant growths while the fake treatment group had 423 patients diagnosed with 470 cancers. The FDA additionally revealed that the more extended a patient was on Belviq, the more noteworthy the expanded danger of getting cancer. Early examinations performed on rats as well indicated that Belviq may cause cancer. Preceding the medication’s endorsement in 2012, producers associated Belviq to an expanded rate of cancerous tumors in rats. The FDA was worried about the discoveries; however, the dangers were not esteemed critical enough to pull Belviq from the markets. The FDA has turned around its position following the 2020 research that indicated conclusive proof connecting Belviq and cancer.
Other Belviq Dangers
The FDA suggested individuals taking Belviq or Belviq XR quickly quit taking the medication following exploration discoveries binds the medicine to expanded malignant growth risk. The prescription as well presents various dangers and symptoms. It’s essential to take note that the medication was just affirmed for individuals who are obese (with a body mass of at least 30) or overweight (with a BMI somewhere in the range of 27 and 30) and have hypertension, elevated cholesterol, or diabetes.
Belviq’s symptoms also include:
- Headaches
- Dizziness
- Exhaustion
- Vomiting
Patients with diabetes who take lorcaserin can likewise be facing back pain, coughing, and hypoglycemia because of taking the medication. Lorcaserin can equally cause heart valve issues and decelerated heartbeat. The Drug Enforcement Agency orders the medicine as a Schedule IV controlled substance referring to dangers of addiction; individuals who take more than endorsed may encounter illusions, slowed thinking, and ecstasy.
The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.
